Satsuma Pharmaceuticals, Inc. Common Stock
STSA
STSA was delisted on the 7th of June, 2023.
60 hedge funds and large institutions have $167M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 25 reducing their positions, and 13 closing their positions.
22% more capital invested
Capital invested by funds: $137M → $167M (+$30.3M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
2% less funds holding
Funds holding: 61 → 60 (-1)
40% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 25
68% less call options, than puts
Call options by funds: $88K | Put options by funds: $278K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$3.59M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.48M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.33M |
| 4 |
SC
Samlyn Capital
New York
|
+$1.9M |
| 5 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$783K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.96M |
| 2 |
BlackRock
New York
|
-$2.47M |
| 3 |
Morgan Stanley
New York
|
-$1.21M |
| 4 |
State Street
Boston,
Massachusetts
|
-$935K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$826K |
STSA Hedge Fund Activity: Q2 2021 in Review
60 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q2 2021, worth a combined $167M — up 22% from $137M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of STSA and 12 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 15 added.
The largest buyer was Commodore Capital, adding an estimated $3.59M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $2.96M sold.
- 60 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q2 2021, down from 61 in Q1 2021.
- Funds reported $167M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q2 2021, up 22% quarter-over-quarter.
- 12 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q2 2021 and 13 closed out, a net change of -1 holder.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q2 2021 was Commodore Capital, an estimated $3.59M added.
- The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q2 2021 was Point72 Asset Management, an estimated $2.96M sold.
Based on aggregated 13F filings for Q2 2021.